Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $41.50.

A number of research analysts recently issued reports on ALGS shares. Westpark Capital started coverage on Aligos Therapeutics in a report on Thursday. They issued a “buy” rating and a $48.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group started coverage on shares of Aligos Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Wall Street Zen cut shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Aligos Therapeutics Trading Up 4.2%

NASDAQ ALGS traded up $0.29 during trading hours on Thursday, reaching $7.25. 27,490 shares of the company’s stock were exchanged, compared to its average volume of 55,044. The firm has a fifty day moving average of $7.35 and a 200-day moving average of $8.77. Aligos Therapeutics has a one year low of $3.76 and a one year high of $13.69. The stock has a market cap of $44.88 million, a PE ratio of -0.82 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.09) by $0.18. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. As a group, research analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Trading of Aligos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. increased its stake in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new position in shares of Aligos Therapeutics in the 3rd quarter valued at $98,000. Susquehanna International Group LLP acquired a new position in shares of Aligos Therapeutics in the 3rd quarter valued at $99,000. XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the 2nd quarter valued at $100,000. Finally, HRT Financial LP bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at $106,000. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.